These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35380034)

  • 1. Safety of an Inactivated SARS-CoV-2 Vaccine Among Healthcare Workers in Turkey: An Online Survey.
    Baydar O; Özen Ş; Öztürk Şahin B; Köktürk N; Kitapçı MT
    Balkan Med J; 2022 May; 39(3):193-198. PubMed ID: 35380034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Investigation of Humoral and Cellular Immunity in TOBB ETÜ Hospital Workers After Three Doses of CoronaVac Vaccination and after One Dose of Comirnaty Vaccination Following Two Doses of CoronaVac].
    Özyurda F; Ardıçoğlu Akışın Y; Mert T; Poyraz B; Özkan Y; Turan M; Göçmen JS; Yücel A; Akar N
    Mikrobiyol Bul; 2022 Jul; 56(3):387-403. PubMed ID: 35960233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
    Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
    Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
    Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience.
    Yigit M; Ozkaya-Parlakay A; Cosgun Y; Ince YE; Bulut YE; Senel E
    J Med Virol; 2022 Jan; 94(1):287-290. PubMed ID: 34487373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China.
    Zhang MX; Zhang TT; Shi GF; Cheng FM; Zheng YM; Tung TH; Chen HX
    Expert Rev Vaccines; 2021 Jul; 20(7):891-898. PubMed ID: 33929930
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse events report of inactivated COVID-19 vaccine from 4040 healthcare workers.
    Tosun S; Ozkan Ozdemir H; Erdogan E; Akcay S; Aysin M; Eskut N; Ortan P; Eskut B
    Postgrad Med; 2022 Jan; 134(1):104-110. PubMed ID: 34705583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers.
    Soysal A; Gönüllü E; Karabayır N; Alan S; Atıcı S; Yıldız İ; Engin H; Çivilibal M; Karaböcüoğlu M
    Hum Vaccin Immunother; 2021 Nov; 17(11):3876-3880. PubMed ID: 34324409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Adverse Effects of Inactive SARS-Cov-2 Vaccine (CoronaVac) in Health Care Professionals.
    Guzel EC; Yildiz T; Buyukkiyici O; Dombaz OE
    J Pak Med Assoc; 2022 Sep; 72(9):1792-1796. PubMed ID: 36280978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.
    Kadali RAK; Janagama R; Peruru S; Gajula V; Madathala RR; Chennaiahgari N; Malayala SV
    J Med Virol; 2021 Jul; 93(7):4420-4429. PubMed ID: 33822361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2.
    Cheng Y; Li T; Zheng Y; Xu B; Bi Y; Hu Y; Zhou YH
    Hum Vaccin Immunother; 2022 Nov; 18(5):2064134. PubMed ID: 35452357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a hospital-wide campaign on COVID-19 vaccination uptake among healthcare workers in the context of raised concerns for life-threatening side effects.
    Kim MH; Son NH; Park YS; Lee JH; Kim DA; Kim YC
    PLoS One; 2021; 16(10):e0258236. PubMed ID: 34597333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
    Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
    J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of an inactivated COVID-19 vaccine (CoronaVac) in children aged 7-14 years in Taizhou, China.
    Zhang DS; Bao XP; Zhu JJ; Zheng WJ; Sun LX
    Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116253. PubMed ID: 38507964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer.
    Han Y; Yang J; He D; Feng Y; Liu X; Min Y; Fan S; Yin G; Hu D
    Front Immunol; 2022; 13():855311. PubMed ID: 35634276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers.
    Lounis M; Rais MA; Bencherit D; Aouissi HA; Oudjedi A; Klugarová J; Pokorná A; Klugar M; Riad A
    Front Public Health; 2022; 10():896343. PubMed ID: 35651866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran.
    Zare H; Rezapour H; Mahmoodzadeh S; Fereidouni M
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108351. PubMed ID: 34801416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.